Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Antianginal Drugs: Nitrates and β-Blockers

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

Angina V: Nursing Management

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cost-Effectiveness of Risk-Based Screening for Asymptomatic Carotid Artery Stenosis.

MDM policy & practice·2026

Same author

Effect of Systolic Blood Pressure Measurement Error on the Cost-Effectiveness of Intensive Blood Pressure Targets.

Annals of internal medicine·2025

Same author

Acute Ischemic Stroke Care Quality Improvement.

JAMA neurology·2025

Same author

Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison.

AJR. American journal of roentgenology·2024

Same author

Cost-Effectiveness of Screening Asymptomatic Carotid Stenosis by Atherosclerotic Cardiovascular Risk.

medRxiv : the preprint server for health sciences·2024

Same author

Reply.

Journal of the American College of Radiology : JACR·2024

Search research articles

Related Experiment Video

Updated: May 9, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Antianginal therapy before percutaneous coronary intervention.

William B Borden¹, John A Spertus, Alvin I Mushlin

¹Department of Public Health, Weill Cornell Medical College, New York, NY 10065, USA. wbb2001@med.cornell.edu

Circulation. Cardiovascular Interventions

|August 8, 2013

Summary

Regional variations in percutaneous coronary intervention (PCI) rates are not linked to antianginal medication use. Further research is needed to understand differing PCI rates and improve antianginal therapy before elective PCI procedures.

Keywords:

angina, stable angioplasty coronary disease stents

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Experiment Videos

Last Updated: May 9, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Area of Science:

Cardiology
Health Services Research
Pharmacology

Background:

Regional variations in percutaneous coronary intervention (PCI) rates may stem from differing medical management of stable coronary artery disease.
Investigating the link between antianginal medication use and PCI rates is crucial for understanding care disparities.

Purpose of the Study:

To determine if higher regional use of antianginal medications correlates with lower regional rates of PCI for stable coronary artery disease.
To analyze the association between antianginal therapy intensity and PCI utilization across different geographic areas.

Main Methods:

Utilized data from the CathPCI Registry and Dartmouth Atlas for elective PCI patients (2009-2011).
Calculated regional rates of providing at least two antianginal medications before PCI.
Regressed regional PCI rates against rates of antianginal medication use.

Main Results:

Over 300,000 PCI procedures were analyzed; 18.9% of patients received ≥ 2 antianginal medications before PCI.
Significant regional variability was observed in both antianginal medication use and PCI rates.
No statistically significant association was found between regional PCI rates and the intensity of pre-PCI antianginal therapy (Spearman ρ = 0.0277, P = 0.64).

Conclusions:

The intensity of antianginal therapy does not appear to influence regional percutaneous coronary intervention rates.
Opportunities exist to increase antianginal therapy use before elective PCI in many regions.
Further research is required to elucidate the factors driving observed variations in PCI utilization.